Last $15.05 USD
Change Today +0.58 / 4.01%
Volume 1.0M
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Christopher T. Walsh M.D., Ph.D.

Scientific Advisor, Director, Member of Pharmaceuticals Advisory Committee and Member of Governance & Nominating Committee, Ironwood Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 115 board members in 8 different organizations across 11 different industries.

See Board Relationships
70$47,500

Background*

Mr. Christopher T. Walsh, also known as Chris, M.D., Ph.D., serves as a Scientific advisor of Ironwood Pharmaceuticals, Inc. Mr. Walsh serves as an Advisor of LS9, Inc. He has been Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology of Harvard Medical School since June 1987. He is a Co-Founder of Magen BioSciences, Inc. He served as President of the Dana-Farber Cancer Institute from 1992 to 1995. He served as Corporate Secretary of TransForm Pharmaceuticals, ...

Read Full Background

Corporate Headquarters*

301 Binney Street
Cambridge, Massachusetts 02142

United States

Phone: 617-621-7722
Fax: 617-494-0480

Board Members Memberships*

Corporate Secretary and Director
Co-Founder, Director and Member of Scientific Advisory Board
Director
1996-Present
Director, Chairman of Corporate Governance & Nominating Committee, Member of Compensation Committee and Member of Strategic Advisory Committee
1996-N/A
Former Director
1998-N/A
Former Director, Member of Audit Committee, Member of Compensation Committee and Member of Nominating Committee
2001-2007
Former Director
2003-Present
Scientific Advisor, Director, Member of Pharmaceuticals Advisory Committee and Member of Governance & Nominating Committee
2008-Present
Director and Member of Nominating & Corporate Governance Committee

Education*

PhD
Rockefeller University
BA
Harvard College

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$47,500
Total Calculated Compensation$47,500
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $15.05 USD +0.58

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Rick E. Winningham Chairman, Chief Executive Officer, Member of Stock Option Committee and Member of Science & Technology Advisory Committee
Theravance Inc.
$986.9K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
--
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
$620.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.